Its up 0.26, from 1.28 in 2017Q2.
Millennium Lc has invested 0% in Atara Biotherapeutics, Inc. Wells Fargo & Mn holds 55,151 shares or 0% of its portfolio. Voya Investment Management LLC increased its holdings in Atara Biotherapeutics by 16.2% in the second quarter. (NASDAQ:ATRA) is noted at 1.93. Proshare Advsr Limited Liability Co invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) from a sell rating to a hold rating in a report issued on Wednesday. Legal And General Gru Plc accumulated 6,994 shares. See Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 30,095 shares. Neuberger Berman Grp Inc Llc invested in 0.02% or 1.12 million shares. Ani Pharmaceuticals Inc now has $823.16M valuation. The SI to Atara Biotherapeutics Incorporated's float is 47.13%. The short ratio for ATRA is 12.49 while that of OPGN is just 2.55. Ameritas Invest Prtnrs Incorporated has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Schwab Charles Inv Mngmt stated it has 0% of its portfolio in Atara Biotherapeutics, Inc.
Since August 10, 2017, it had 0 buys, and 16 sales for $2.51 million activity. 4,200 Atara Biotherapeutics, Inc. BidaskClub upgraded Atara Biotherapeutics from a "hold" rating to a "buy" rating in a report on Thursday, January 11th. Atara Biotherapeutics, Inc.is headquartered in Brisbane, California.
Several hedge funds have recently added to or reduced their stakes in ATRA. (NASDAQ:ATRA) for 25,520 shares. Bank of New York Mellon Corp now owns 125,713 shares of the biotechnology company's stock valued at $1,760,000 after purchasing an additional 5,616 shares in the last quarter. During last 3 month period, 0.03% of total institutional ownership has changed in the company shares.
Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) opened at $28.25 on Thursday. It has underperformed by 16.70% the S&P500. It was reported on Jan, 17 by Barchart.com. A reading above 70 indicates that a stock is overvalued, and a reading below 30 implies that it is undervalued. (NASDAQ:ATRA) to report earnings on March, 8. While in the same Quarter Previous year, the Actual EPS was $-0.63.
Atara Biotherapeutics, Inc. has a consensus outperform rating from 6 Wall Street analysts, and the number of shares now sold short amount to at least 19.12% of shares outstanding. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Therefore 67% are positive. Analysts have placed a $29.6 price target on Atara Biotherapeutics, Inc., suggesting a 7.44% gain from recent close. Citigroup maintained it with "Sell" rating and $8 target in Friday, August 19 report. The firm earned "Market Outperform" rating on Tuesday, December 15 by JMP Securities. William Blair initiated the stock with "Outperform" rating in Friday, October 9 report. But shareholders expect them to benefit in the long run from the decision to cut the standard tax rate from 35 percent to 21 percent and are bidding up their share prices. On Wednesday, November 18 the stock rating was initiated by Goldman Sachs with "Neutral". The company was reinitiated on Thursday, June 22 by Jefferies. Its most recent closing price has a distance of 54.82% from SMA20 and is 83.31% above than SMA200.
This stock (ATRA) is ahead of its 52-week low with 133.47%.
The bad news is analysts don't believe there's a room for Yuma Energy, Inc.
(NASDAQ:ATRA) were released by: Benzinga.com and their article: "Mid-Day Market Update: ADTRAN Drops On Weak Q4 Guidance; Atara Biotherapeutics ..." published on December 29, 2017 as well as Seekingalpha.com's news article titled: "Atara Biotherapeutics: What The FDA Clearance For ATA-188 Phase 1 Study At US ..." with publication date: January 12, 2018.
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $864.33 million. The Company's clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus.